Saniona: Important news considering the circumstances
The announcement by Saniona that the last patient in completes the last visit in the phase 2a study in Hypothalamic Obesity (HO) is important news, considering the current circumstances of the pandemic outbreak of the Covid-19. The trial is on track to report top-line results in Q2’20.